3rd - 6th Dec 2016
Dr Mascarenhas speaks with ecancertv at ASH 2016 about pacritinib, an oral kinase inhibitor against JAK2, FLT3, IRAK1, and CSF1R.
He describes the patient response to pacritinib, with a direct comparison to ruxolitinib (a JAK1/2 inhibitor) being of significant interest, and weighs measuring spleen volume reduction against other endpoints.
Pacritinib is currently on full clinical hold by the FDA following deaths and cardiac events in PERSIST-1, which Dr Mascarenhas considers against the toxicity profile in this trial.
ecancer's filming at ASH 2016 has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.